Please login to the form below

Not currently logged in
Email:
Password:

Seragon

This page shows the latest Seragon news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

  • Chugai soars on Roche buyout rumours Chugai soars on Roche buyout rumours

    Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing

  • Roche makes $1.7bn oncology acquisition Roche makes $1.7bn oncology acquisition

    According to Roche, this pipeline of products complements the breast cancer programmes of its biotech division Genentech, which will assume control of Seragon. ... Seragon was only created last year when it was spun out from cancer drug specialist Aragon

  • J&J completes Aragon deal as Seragon is born J&J completes Aragon deal as Seragon is born

    Seragon spun out. The closure of the deal also sees the creation of a new pharma company - Seragon Pharmaceuticals - that will take over development of other Aragon development programmes, including metastatic ... Seragon is focused on developing new

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    Roche – in and out and round about. Following on from last month's $1.73bn acquisition of Seragon Pharmaceuticals, Roche seems to be in mood-swing mode backing out of one

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    2, 095. Seragon Pharmaceuticals/ Genentech. Company acquisition   . Selective Estrogen Receptor Degrader (SERD) platform for hormone dependent breast cancer, inc ARN-810 (p1).

  • Pharma deals during July 2014 Pharma deals during July 2014

    At the very start of the month, Genentech announced its intention to buy Seragon Pharmaceuticals for $725m cash upfront with $1bn-worth of contingent development milestones downstream. Only founded in August ... 2013, Seragon is a venture-backed company

  • Pharma deals during June 2013 Pharma deals during June 2013

    Interestingly, J&J is not getting the entire company pipeline however, as Aragon is spinning out the selective oestrogen receptor degrader platform into a new company, Seragon Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics